Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
211At-MABG in Advanced Neuroendocrine Cancers
NCT07661420Phase 1Not yet recruiting
- Sponsor
- University of Pennsylvania
- Start
- Dec 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of astatobenguane [211At] in Neuroendocrine Neoplasm (NEN), pheochromocytoma, Paraganglioma (PGL) and 3 more (3 arms), sponsored by University of Pennsylvania. Primary endpoints: Overall Study Feasibility at 4 weeks and Study Feasibility Assessed for Operational Issues Versus Treatment-Related Adverse Events at 4 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
astatobenguane [211At]
03
Conditions
Neuroendocrine Neoplasm (NEN)pheochromocytomaParaganglioma (PGL)Medullary Thyroid Cancer (MTC)bronchial carcinoid tumor
Beyond the preview
Go deeper on NCT07661420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661420.